DTech Liquidating

DTech Liquidating EV/Revenue

Delisted

The EV/Revenue (Enterprise Value to Revenue) of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is -3.65. In the previous year, EV/Revenue (Enterprise Value to Revenue) was -8.68 — a change of -57.95% (higher).

EV/Revenue

-3.65

YoY

-57.95%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of DTech Liquidating is 2023 -3.65 . EV/Revenue (Enterprise Value to Revenue) of DTech Liquidating was 2022 -8.68 . It decreases by -57.95% higher compared to the previous year.

The DTech Liquidating EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2019
-4.58 USD
Jan 1, 2020
-10.78 USD
Jan 1, 2021
-19.00 USD
Jan 1, 2022
-8.68 USD
Jan 1, 2023
-3.65 USD
The DTech Liquidating EV/Revenue history
YEAREV/RevenueYoY
-3.65-57.95%
-8.68-54.34%
-19.00+76.27%
-10.78+135.22%
-4.58—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

EV/Revenue (Enterprise Value to Revenue) of DTech Liquidating is -3.65 in 2023.

EV/Revenue (Enterprise Value to Revenue) of DTech Liquidating changed from -8.68 to -3.65, representing a -57.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — DTech Liquidating

All Key Metrics — DTech Liquidating